Navigation Links
Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016
Date:2/25/2008

Entry of Novel Therapies Including Rituxan/MabThera and Increased Uptake of CellCept Will Provide Effective Treatment Options, According to a New

Report from Decision Resources

WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry and uptake of high-priced branded agents will drive the systemic lupus erythematosus drug market to quadruple from approximately $325 million in 2006 to $1.4 billion in 2016.

The new Pharmacor report entitled Systemic Lupus Erythematosus finds that the strongest drivers of market growth will be the formal approval of several therapies that target B cells, including Biogen Idec/Genentech/Zenyaku Kogyo's Rituxan/Roche's MabThera, as well as increased uptake of Roche/Aspreva Pharmaceuticals' branded immunosuppressant CellCept.

"The introduction of novel biologics, other targeted therapies, and immunosuppressants into the treatment regimens of patients with systemic lupus erythematosus will result in increased polypharmacy," said Amy Whiting, Ph.D., analyst at Decision Resources. "These agents will not replace existing therapies but rather be used in combination with existing drugs to provide more-effective and/or safer treatment."

The report finds that sales in the systemic lupus erythematosus drug market will experience a significant 24% annual increase between 2006 and 2011. Sales growth will then proceed at a slower pace of 9% annually from 2011 to 2016, owing to fewer new product launches, generic erosion of CellCept, and biogeneric erosion of Rituxan/MabThera.

About Systemic Lupus Erythematosus

Systemic lupus erythematosus is an autoimmune disease characterized by a complex pathophysiology that results in widespread tissue damage of multiple organ systems. The disease affects more than 537,000 people in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The diagnosed prevalence of systemic lupus erythematosus is approximately ten times higher in women than in men.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform
2. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
3. The Branded Pharmaceutical Association Comments on Hydrocodone
4. FTCR: Gov. Schwarzenegger Must Follow Through on Call to Ban Blue Cross From Using Doctors as Double-Agents to Dump Sick Patients
5. ABR-Affinity BioReagents Participates in the 2008 Fisher Scientific Supplier Expo in San Antonio, Texas
6. LiquidAgents Healthcare, LLC Awarded Accreditation from the Joint Commission
7. Insurance Agents Call for State Senate to Improve Californias Health Care Reform Compromise
8. Allergic reactions to gadolinium-based contrast agents are rare, study finds
9. Germ-Fighting Inhaler Could Fend Off Bioterror Agents
10. National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)
11. Benepath Launches Exclusive Marketing Service for Health Insurance Agents and Agencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
Breaking Medicine Technology: